Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
NCT ID: NCT00205478
Last Updated: 2007-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
300 participants
INTERVENTIONAL
2005-06-30
2006-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VX-702
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vertex Pharmaceuticals Incorporated
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Kauffman, MD, PhD
Role: STUDY_DIRECTOR
Vertex Pharmaceuticals Incorporated
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical University - Sofia
Sofia, , Bulgaria
Military Medical Academy - Sofia
Sofia, , Bulgaria
Transport Hospital
Sofia, , Bulgaria
MBAL "Stara Zagora" EAD
Stara Zagora, , Bulgaria
Thalassotherapia
Opatija, , Croatia
KBC Osijek Ambulanta za bol
Osijek, , Croatia
University Hospital Centre Zagreb
Zagreb, , Croatia
University Hospital U Sv.Anny
Brno, , Czechia
Institute of Rheumatology
Prague, , Czechia
Rheumatology Out-patient Department
Prague, , Czechia
SZZ-Jizni Mesto II
Prague, , Czechia
University Hospital Kralovske Vinohrady
Prague, , Czechia
Szpital Specjalistyczny Nr 1
Bytom, , Poland
Wojewodzki Szpital Zespolony
Elblag, , Poland
Malopolskie Centrum Medyczne
Krakow, , Poland
"Gabinety Profesorow" Prywatna Praktyka
Lublin, , Poland
Instytut Medycyny Wsi im. Witolda Chodzki
Lublin, , Poland
Wojewodzki Zespoￅﾂ Reumatologiczny im.
Sopot, , Poland
NZOZ "Nasz Lekarz" Praktyka Grupowa Lekarzy
Torun, , Poland
Okregowy Szpital Kolejowy
Wroclaw, , Poland
ZOZ Zyrardow
Żyrardów, , Poland
Pirogov City Clinical Hospital #1
Moscow, , Russia
State Institute of Rheumatology of RAMS
Moscow, , Russia
State Clinical Immunology Research
Novosibirsk, , Russia
Ryazan Regional Clinical Cardiologic
Ryazan, , Russia
City Pokrovskaya Hospital
Saint Petersburg, , Russia
EVIDENCE Clinical and Pharmaceutical Research
Saint Petersburg, , Russia
Leningrad Regional Hospital
Saint Petersburg, , Russia
Saint Petersburg Clinical Hospital
Saint Petersburg, , Russia
Saint-Petersburg City Hospital
Saint Petersburg, , Russia
Saint-Petersburg Medical Academy
Saint Petersburg, , Russia
Saratov Regional Clinical Hospital
Saratov, , Russia
Institute of Rheumatology
Beograd, , Serbia and Montenegro
Institute of Rheumatology - Niska Banja
Niska Banja, , Serbia and Montenegro
Clinical Center Zemun
Zemun, , Serbia and Montenegro
National Institute of Rheumatic Diseases
Piešťany, , Slovakia
Clinical Center Ljubljana
Ljubljana, , Slovenia
Dniepropetrovsk State Medical Academy
Dniepropetrovsk, , Ukraine
Donetsk State Medical University
Donetsk, , Ukraine
Institute of Cardiology of Ukranian AMS
Kiev, , Ukraine
Institute of Gerontology of Ukrainian AMS
Kiev, , Ukraine
SanaClis s.r.o.
Kiev, , Ukraine
Zaporizhya Medical Institute
Zaporizhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. doi: 10.1002/art.24485.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VX04-702-301
Identifier Type: -
Identifier Source: org_study_id